Phase 2 N=39 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
Advanced Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Objective Response (Partial and Complete) Per RECIST — 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Advanced Malignant Mesothelioma · Localized Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…
Phase 2 N=32 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants
Phase 3 N=144 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Pleural Mesothelioma Malignant Advanced
Primary: Progression Free Survival (PFS) as Assessed by Independent Radiological Review — 2.5; 3.4 months — p=0.76
Phase 3 N=520 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Mesothelioma
Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months
Phase 2 N=77 Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
Pleural Neoplasms
Primary: Pathological Complete Response — 3 participants
Phase 2 N=54 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Overall Response Rate — 9 percentage of participants
Phase 2 N=61 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Malignant Mesothelioma
Primary: Progression-Free Survival — 3.0 months
Phase 2 N=53 Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Mesothelioma
Primary: Progression Free Survival Rate at 6 Months — 56 percentage of participants
Phase 2 N=248 Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Mesothelioma
Primary: Progression-free Survival (PFS), [95% CI] — 4.3; 4.5 months — p=0.859125
Phase 2 N=65 Pembrolizumab in Treating Patients With Malignant Mesothelioma
Biphasic Mesothelioma · Epithelioid Mesothelioma · Peritoneal Malignant Mesothelioma
Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index
Phase 2 N=24 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Mesothelioma
Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109
Phase 2 N=51 Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Localized Malignant Mesothelioma
Primary: Objective Response Rate, Complete (CR) or Partial (PR) Response — 5 percentage of participants
Phase 2 N=45 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Mesothelioma · Adenocarcinoma of Lung · Pancreatic Neoplasms
Primary: Response Assessment — 0; 0; 0; 0 Participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=34 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Malignant Pleural Mesothelioma · Mesothelioma
Primary: Disease Control Rate (DCR) — 75 percentage of participants
Phase 2 N=26 Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Lung Cancer · Mesothelioma
Primary: Disease Control Rate at 4 Months — 8 Participants
Phase 2 N=11 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Malignant Pleural Mesothelioma
Primary: To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated…
Phase 3 N=400 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Pleural Mesothelioma Malignant Advanced
Primary: Overall Survival (OS) — 20.5; 18.1 months — p=0.14
Phase 3 N=400 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Malignant Pleural Mesothelioma
Primary: Overall Survival (OS) — 8.5; 8.0 months — p=0.58
Phase 2 N=89 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
Malignant Pleural Mesothelioma
Primary: Number of Participants With Progression Free Survival (PFS) Responders and Non-responders at Month 6 — 26; 51 Participants
Phase 2 N=47 Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
Mesothelioma; Lung
Primary: To Evaluate the Efficacy of the Treatment — 1.9 Months
Phase 2 N=20 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Pleural Mesothelioma · Peritoneal Mesothelioma
Primary: Clinical Response Rate (PR+CR) — 0; 0 Participants
Phase 3 N=53 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma
Primary: Overall Survival — 17.6; 15.5 Months — p=0.2840
Phase 2 N=55 Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Mesothelioma · Pleural Mesothelioma
Primary: Overall Survival (OS) — 20.4 months
Phase 2 N=13 PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee — 0 percentage of participants
Phase 2 N=2 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Mesothelioma · Peritoneal Mesothelioma
Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery
Phase 2 N=53 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Malignant Mesothelioma
Primary: Progression-free Survival — 3.0; 3.4 months
Phase 2 N=20 Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Recurrent Pleural Malignant Mesothelioma · Stage IV Pleural Mesothelioma
Primary: Progression-free Survival (PFS) — 1.8 months
Phase 1 N=21 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Mesothelioma
Primary: Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel — 140; 100 mcg